AstraZeneca (AZN) and MedImmune announced that its Phase III trial of Imfinzi met a primary endpoint of statistically-significant and clinically-meaningful progression-free survival in 'all-comer' patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer.
from RTT - Before the Bell http://ift.tt/2qn6ZG4
via IFTTT
No comments:
Post a Comment